Does race impact functional outcomes in patients undergoing robotic partial nephrectomy? by Falagario, Ugo G et al.
Providence St. Joseph Health 
Providence St. Joseph Health Digital Commons 
Articles, Abstracts, and Reports 
4-1-2020 
Does race impact functional outcomes in patients undergoing 
robotic partial nephrectomy? 




Kennedy E Okhawere 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.psjhealth.org/publications 
 Part of the Surgery Commons, and the Urology Commons 
Recommended Citation 
Falagario, Ugo G; Martini, Alberto; Pfail, John; Treacy, Patrick-Julien; Okhawere, Kennedy E; Dayal, 
Bheesham D; Sfakianos, John P; Abaza, Ronney; Eun, Daniel D; Bhandari, Akshay; Porter, James R; Hemal, 
Ashok K; and Badani, Ketan K, "Does race impact functional outcomes in patients undergoing robotic 
partial nephrectomy?" (2020). Articles, Abstracts, and Reports. 3143. 
https://digitalcommons.psjhealth.org/publications/3143 
This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has 
been accepted for inclusion in Articles, Abstracts, and Reports by an authorized administrator of Providence St. 
Joseph Health Digital Commons. For more information, please contact digitalcommons@providence.org. 
Authors 
Ugo G Falagario, Alberto Martini, John Pfail, Patrick-Julien Treacy, Kennedy E Okhawere, Bheesham D 
Dayal, John P Sfakianos, Ronney Abaza, Daniel D Eun, Akshay Bhandari, James R Porter, Ashok K Hemal, 
and Ketan K Badani 
This article is available at Providence St. Joseph Health Digital Commons: https://digitalcommons.psjhealth.org/
publications/3143 
  Transl Androl Urol 2020;9(2):863-869 | http://dx.doi.org/10.21037/tau.2019.09.31© Translational Andrology and Urology. All rights reserved.
Original Article on Robotic-assisted Urologic Surgery
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Background: The role of race on functional outcomes after robotic partial nephrectomy (RPN) is still 
a matter of debate. We aimed to evaluate the clinical and pathologic characteristics of African American 
(AA) and Caucasian patients who underwent RPN and analyzed the association between race and functional 
outcomes.
Methods: Data was obtained from a multi-institutional database of patients who underwent RPN in  
6 institutions in the USA. We identified 999 patients with complete clinical data. Sixty-three patients (6.3%) 
were AA, and each patient was matched (1:3) to Caucasian patients by age at surgery, gender, Charlson 
Comorbidity Index (CCI) and renal score. Bivariate and multivariate logistic regression analyses were used 
to evaluate predictors of acute kidney injury (AKI). Kaplan-Meier method and multivariable semiparametric 
Cox regression analyses were performed to assess prevalence and predictors of significant eGFR reduction 
during follow-up. 
Results: Overall, 252 patients were included. AA were more likely to have hypertension (58.7% vs. 35.4%, 
P=0.001), even after 1:3 match. Overall 42 patients (16.7%) developed AKI after surgery and 35 patients 
(13.9%) developed significant eGFR reduction between 3 and 15 months after RAPN. On multivariate 
analysis, AA race did not emerge as a significant factor for predicting AKI (OR 1.10, P=0.8). On Cox 
multivariable analysis, only AKI was found to be associated with significant eGFR reduction between 3 and 
15 months after RAPN (HR 2.49, P=0.019).
Conclusions: Although African American patients were more likely to have hypertension, renal function 
outcomes of robotic partial nephrectomies were not significantly different when stratified by race. However, 
future studies with larger cohorts are necessary to validate these findings.
Keywords: Acute kidney injury (AKI); chronic kidney disease (CKD); functional outcome; partial nephrectomy
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Introduction
African Americans (AA) constitute about 12% of the USA 
population (1). It has been estimated that AA patients 
presenting with renal cell carcinoma (RCC) are more likely 
to present with localized disease as compared to Caucasians 
at diagnosis. However, prior studies have demonstrated 
that AA race is associated with worse survival outcomes 
(2-5). This fact may be attributed to differences in tumor 
biology (6), socioeconomic status or functional outcomes (7). 
Additionally, AA have a higher probability of developing 
chronic kidney disease (CKD) at a younger age relative 
to Caucasians and are also more likely to present with 
comorbidities such as diabetes and hypertension (8). 
It is common knowledge that the blood pressure lowering 
efficacy of renin-angiotensin system (RAS) inhibitors is 
attenuated in African Americans. This is due to a higher 
prevalence of salt sensitivity, which is defined as an increase 
in blood pressure in response to sodium or salt intake and is 
commonly associated with a low circulating renin profile (9). 
Therefore, inhibitors of the RAS are often not recommended 
as initial antihypertensive therapy. The reasons behind 
this phenomenon have not been fully explored but may 
likely be linked to socioeconomic status, lifestyle choices, 
environmental, and biologic/genetic factors that may 
contribute broadly to racial/ethnic differences in outcomes, 
as well as in response to therapeutic intervention (10). 
Wilson et al. hypothesized that the slave trade from 
Africa to the Americas led to extreme volume depletion 
and cardiovascular collapse during the journey due to 
diarrheal diseases and limited access to water. These 
extreme conditions favored the survival of people who 
were avid sodium retainers and accelerated gene selection 
for sodium retention (11). Given this racial disparity 
and the implications of the kidney function after partial 
nephrectomy on the overall survival and cancer specific 
survival (12,13), we aimed to determine the functional 
outcomes of AA patients were undergoing RAPN. 
Methods
Patient population
We retrospectively reviewed a multi-institutional database 
of 1,150 patients who underwent RAPN. Patients with 
missing data were excluded from the analysis [Charlson 
Comorbidity Index (CCI), n=17 and RENAL nephrometry 
score, n=134]. Overall, 999 patients were considered for 
further analyses. All patients were operated on by six expert 
surgeons from six different institutions and had complete 
clinical, perioperative and relatively short-term outcome 
data. Overall, there were 63 AA patients (6.3%), who were 
matched (1:3) to Caucasians by age at surgery, gender, CCI 
and RENAL nephrometry score.
Outcomes and variable definitions
Estimated GFR was calculated according to the Chronic 
Kidney Disease Epidemiology Collaboration formula (14). 
To investigate kidney function after robot-assisted partial 
nephrectomy (RAPN), two outcomes were selected: (I) AKI 
defined according to the risk/injury/failure/loss/end-stage 
(RIFLE) criteria (>25% reduction in preoperative baseline 
eGFR or >1.5-fold increase in preoperative creatinine, both 
at discharge from hospital) (15) and (II) eGFR reduction of 
>25% from baseline between 3 and 15 months after RAPN. 
This eGFR threshold was chosen based on the National 
Institute for Health and Care Excellence guidelines for 
CKD (16). Covariates included in the analyses included age, 
race, gender, BMI, diabetes and hypertension, CCI, baseline 
eGFR, RENAL nephrometry score and ischemia time.
Statistical analysis
Descriptive statistics were performed to determine the 
distribution of the overall population stratified by race. 
Continuous variables were reported as median and 
interquartile range and compared by the Kruskal-Wallis 
test. Categorical variables were reported as frequencies and 
percentages and were compared using Fisher’s exact test or 
chi-square test, as appropriate. 
We performed univariable and multivariable analyses to 
evaluate predictors of AKI. 
The incidence rate of significant eGFR reduction in AA 
and Caucasian patients was estimated nonparametrically 
using the Kaplan-Meier method. Finally, multivariable 
semiparametric Cox regression analyses were performed 
to assess predictors of significant eGFR reduction during 
follow-up. Statistical analyses were conducted using R (for 
matching patients) and Stata 14 (for all other analyses). An α 
level of 0.05 was used for evaluating statistical significance.
Results 
Population characteristics
Descriptive characteristics of 252 patients included for 
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analysis are shown in Table 1. There were no significant 
differences between AA and Caucasians in age at surgery, 
gender, body mass index, CCI, baseline eGFR, CKD stage 
based on eGFR, RENAL nephrometry score, ischemia 
time and AKI. However, AA were more likely to have 
hypertension (58.7% vs. 35.4%, P=0.001). 
Functional outcomes
Overall 42 patients (16.7%) developed AKI after surgery 
and 35 patients (13.9%) developed significant eGFR 
reduction between 3 and 15 months after RAPN. Median 
follow-up of patients who did not develop significant eGFR 
Table 1 Descriptive characteristics of the 252 patients who underwent robot assisted partial nephrectomy
Variable Overall (N=252) Caucasian (N=189) African American (N=63) P value
Age, yr 59.5 (51.0, 66.5) 60.0 (51.0, 66.0) 58.0 (50.0, 67.0) 0.8
Sex, n
Female 133 (52.8%) 101 (53.4%) 32 (50.8%) 0.7
Male 119 (47.2%) 88 (46.6%) 31 (49.2%)
BMI, kg/m2 29.4 (25.6, 34.6) 29.4 (25.3, 34.8) 29.4 (26.4, 34.4) 0.8
Hypertension, n
No 148 (58.7%) 122 (64.6%) 26 (41.3%) 0.001
Yes 104 (41.3%) 67 (35.4%) 37 (58.7%)
Diabetes, n
No 202 (80.2%) 155 (82.0%) 47 (74.6%) 0.2
Yes 50 (19.8%) 34 (18.0%) 16 (25.4%)
CCI, n
0 140 (55.6%) 105 (55.6%) 35 (55.6%) 1
1 56 (22.2%) 42 (22.2%) 14 (22.2%)
2 35 (13.9%) 26 (13.8%) 9 (14.3%)
3 21 (8.3%) 16 (8.5%) 5 (7.9%)
Baseline eGFR mL/min/1.73 m2 82.2 (65.2, 96.1) 81.9 (65.7, 95.8) 82.7 (62.7, 101.1) 0.5
GFR category, n
G1 92 (36.5%) 68 (36.0%) 24 (38.1%) 0.8
G2 112 (44.4%) 88 (46.6%) 24 (38.1%)
G3a 35 (13.9%) 24 (12.7%) 11 (17.5%)
G3b 10 (4.0%) 7 (3.7%) 3 (4.8%)
G4 3 (1.2%) 2 (1.1%) 1 (1.6%)
RENAL score 7.0 (5.5, 9.0) 7.0 (5.0, 9.0) 7.0 (6.0, 9.0) 0.9
Ischemia time, min 15.0 (11.9, 21.0) 15.0 (11.5, 20.0) 15.6 (12.0, 21.0) 0.8
AKI, n
No 210 (83.3%) 160 (84.7%) 50 (79.4%) 0.3
Yes 42 (16.7%) 29 (15.3%) 13 (20.6%)
Medians (interquartile range) or frequencies (proportions) are displayed for continuous and categorical variables, respectively. AKI, acute 
kidney injury.
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reduction was 12.35 months. Univariable and multivariable 
logistic regression predicting AKI after RAPN are shown 
in Table 2. In the univariable analyses, only hypertension 
(OR =2.44, P=0.010), diabetes (OR =2.78, P=0.006), and 
ischemia time (OR =1.05, P=0.016) were found to be 
predictors of AKI. After adjusting for these covariates in 
multivariate analysis, AA race did not emerge as a significant 
factor for predicting AKI (OR 1.10, P=0.8). Rates of significant 
eGFR reduction between 3 and 15 months after RAPN are 
shown in Figure 1. There was no significant difference between 
African Americans and Caucasians (P=0.9).
The role of race, AKI, diabetes, and hypertension were 
investigated using multivariable Cox regression analyses, 
and only AKI was found to be associated with significant 
eGFR reduction between 3 and 15 months after RAPN (HR 
2.49, P=0.019) (Table 3).
Discussion
In the last decade, there has been a paradigm shift towards 
a more conservative approach for the treatment of small 
kidney tumors. Partial nephrectomy, by means of the open 
or the robotic approach, currently represents the standard 
of care treatment for T1 renal cancer. African American 
patients are reportedly more likely to be diagnosed earlier 
with localized RCC as compared to Caucasians. However, 
they paradoxically tend to have worse prognosis in terms 
of functional and oncological outcomes. This may partly 
be attributed to differences in tumor biology (6,17), 
socioeconomic status or functional outcomes (12,13). 
Since several studies have shown that functional outcomes 
and kidney function after partial nephrectomy impacts 
overall and cancer specific survival, we aimed to compare 
functional outcomes between African American and 
Caucasian patients. After matching the two populations 
for comorbidities and anatomy and dissection complexity, 
we found that African Americans have similar risk of AKI 
after surgery and significant eGFR reduction within 3 and 
15 months of follow-up. 
Kara et al. reported similar results showing no significant 
differences in the median percentage of eGFR preservation at 
one-year follow-up in 84 AA patients undergoing RPN (18). 
Table 2 Univariable and multivariable logistic regression predicting AKI after robot-assisted partial nephrectomy
Covariate
Univariable analyses Multivariable analysis
OR 95% CI P value OR 95% CI P value
Age 1.01 0.98, 1.05 0.344
Sex
Female 1 Ref.
Male 0.72 0.37, 1.41 0.339
Race
Caucasian
African American 1.43 0.69, 2.97 0.331 1.10 0.50, 2.40 0.809
BMI 1.02 0.97, 1.07 0.453
Hypertension
No 1 Ref. 1 Ref.
Yes 2.44 1.24, 4.80 0.010 2.55 1.13, 5.73 0.024
Diabetes
No 1 Ref. 1 Ref.
Yes 2.78 1.34, 5.75 0.006 1.93 0.85, 4.41 0.117
Baseline eGFR 1.01 0.99, 1.03 0.252
RENAL score 1.09 0.91, 1.31 0.325
Ischemia time 1.05 1.01, 1.10 0.016 1.07 1.02, 1.12 0.003
867Translational Andrology and Urology, Vol 9, No 2 April 2020
  Transl Androl Urol 2020;9(2):863-869 | http://dx.doi.org/10.21037/tau.2019.09.31© Translational Andrology and Urology. All rights reserved.
However, these results may be limited by the methods used 
as the authors performed a matched-paired analysis of AA 
and Caucasians by age, preoperative eGFR and R.E.N.A.L 
score comparing median percentage of eGFR preservation 
at one-year follow-up. To control for this in our study, 
we performed a multivariable semiparametric Cox 
regression analyses to predict a time dependent outcome. 
Moreover, we were able to take into account several known 
confounders such us ischemia time, AKI and hypertension 
which have been found to be significant predictors of worse 
functional outcomes (19-21).
Conflicting results are reported by Wang et al., who 
found a significantly higher increase in serum creatinine 
at discharge among 105 AA patients who underwent RPN 
(0.44 vs. 0.33 mg/dL, P<0.001) (22). However, the author 
did not take into account that AA patients were significantly 
more likely to be affected by diabetes and hypertension. 
Adjusting for these comorbidities, we found no major 
differences in the risk of developing AKI after surgery.
If the results of our findings are confirmed by future 
larger studies, racial disparities in survival outcomes of 
RCCs should be investigated with respect to differences 
in socioeconomic status and treatment or differences 
in tumor biology. Previous reports suggest that factors 
including a higher prevalence of hypertension, smoking, 
alcohol use and lack of access to care underlie this survival 
disparity (4,5,23).
Tripathi et al. examined survival rates of African 
Americans and Caucasians who were diagnosed with 
metastatic kidney cancer and enrolled in clinical trials. 
Randomizing the population minimized bias towards access 
to care, compliance, and performance status. However, AA 
patients continued to have a 44% greater risk of death when 
compared with Caucasian patients with metastatic RCC (24). 
The reasons for the differences in outcome are unknown 
but variations in pathologic, genetic and immunologic 
tumor characteristics may play a relevant role. Molecular 
alterations commonly associated with better prognosis of 
RCC have been found to be less prevalent in the African 
American population. AA patients with clear cell RCC 
have less frequent VHL inactivation and have decreased 
up-regulation of HIF-associated gene signatures than 
white patients. These genomic differences would predict 
decreased responsiveness to VEGF-targeted therapy and 
are a biologically plausible contributing factor to the worse 
survival of AA patients with clear cell RCC (17). Distinct 
tumor biology with differential expression patterns were 
also observed in AA patients with papillary RCC (6). To 
the best of our knowledge, this is the first multi-center 
study comparing African American and Caucasian risk 
of developing AKI and significant eGFR reduction after 
RAPN.
The relationship found between eGFR and overall 
survival, specifically cancer specific mortality, indicates that 
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Figure 1 Kaplan-Meier failure function showing significant eGFR 
reduction probability after robotic assisted partial nephrectomy 
(RAPN) between 3 and 15 months of follow-up. The log-rank test 
did not demonstrate a significant difference between Caucasian 
and African American.
Table 3 Multivariable Cox regression analyses predicting significant 
eGFR reduction between 3 and 15 months after robot-assisted 
partial nephrectomy
Covariate OR 95% CI P value
Race
Caucasian 1 Ref.
African American 0.61 0.28, 1.32 0.207
AKI
No 1 Ref.
Yes 2.49 1.16, 5.36 0.019
Diabetes
No 1 Ref.
Yes 1.40 0.63, 3.08 0.407
Hypertension
No 1 Ref.
Yes 2.00 0.91, 4.40 0.084
Ischemia time 0.99 0.95, 1.04 0.700
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following surgery for RCC. However, the present study 
demonstrates that similar perioperative and intermediate 
term renal function outcomes are achieved in African 
American and Caucasian patients following RPN, even after 
accounting for the presence of hypertension and diabetes. 
Limitations to this study include the relatively small 
sample size, the retrospective nature of the study, and 
the fact that these surgeries were performed by different 
urologists, which may introduce variability among patient 
outcomes. 
Conclusions
Our results, which are based on a matched analysis of 
African American and Caucasian patients who underwent 
RAPN, showed that African American patients tend to have 
similar functional outcomes, in terms of AKI and significant 
eGFR reduction, to Caucasian patients after RAPN. As the 
current study has a relatively small sample size, future larger 
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